Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial

Detalhes bibliográficos
Autor(a) principal: Fuchs, Flávio Danni
Data de Publicação: 2011
Outros Autores: Fuchs, Sandra Cristina Pereira Costa, Moreira, Leila Beltrami, Gus, Miguel, Nobrega, Antonio Claudio Lucas da, Figueiredo, Carlos Eduardo Poli de, Mion Junior, Décio, Bortolotto, Luiz Aparecido, Consolim-Colombo, Fernanda Marciano, Nobre, Fernando, Coelho, Eduardo Barbosa, Martin, Jose Fernando Vilela, Moreno Junior, Heitor, Cesarino, Evandro José, Franco, Roberto Jorge da Silva, Brandão, Andréa Araujo, Sousa, Marcos Roberto de, Ribeiro, Antônio Luiz Pinho, Jardim, Paulo Cesar Brandao Veiga, Afiune Neto, Abrahão, Scala, Luiz César Nazário, Gomes, Marco Antônio Mota, Chaves, Hilton, Alves, João Guilherme Bezerra, Sobral Filho, Dário Celestino, Silva, Ricardo Pereira e, Figueiredo Neto, José Albuquerque de, Irigoyen, Maria Claudia Costa, Castro, Iran, Steffens, André Avelino, Schlatter, Rosane Paixão, Mello, Renato Gorga Bandeira de, Mosele, Francisca, Ghizzoni, Flávia, Silva, Otávio Berwanger da
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/30374
Resumo: Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a populationbased intervention to prevent the incidence of hypertension and the development of target-organ damage. Methods: This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. Discussion: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a populationbased perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil.
id UFRGS-2_45a2577a4d7ea33705343ae91f672942
oai_identifier_str oai:www.lume.ufrgs.br:10183/30374
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Fuchs, Flávio DanniFuchs, Sandra Cristina Pereira CostaMoreira, Leila BeltramiGus, MiguelNobrega, Antonio Claudio Lucas daFigueiredo, Carlos Eduardo Poli deMion Junior, DécioBortolotto, Luiz AparecidoConsolim-Colombo, Fernanda MarcianoNobre, FernandoCoelho, Eduardo BarbosaMartin, Jose Fernando VilelaMoreno Junior, HeitorCesarino, Evandro JoséFranco, Roberto Jorge da SilvaBrandão, Andréa AraujoSousa, Marcos Roberto deRibeiro, Antônio Luiz PinhoJardim, Paulo Cesar Brandao VeigaAfiune Neto, AbrahãoScala, Luiz César NazárioGomes, Marco Antônio MotaChaves, HiltonAlves, João Guilherme BezerraSobral Filho, Dário CelestinoSilva, Ricardo Pereira eFigueiredo Neto, José Albuquerque deIrigoyen, Maria Claudia CostaCastro, IranSteffens, André AvelinoSchlatter, Rosane PaixãoMello, Renato Gorga Bandeira deMosele, FranciscaGhizzoni, FláviaSilva, Otávio Berwanger da2011-07-27T06:00:47Z20111745-6215http://hdl.handle.net/10183/30374000778193Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a populationbased intervention to prevent the incidence of hypertension and the development of target-organ damage. Methods: This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. Discussion: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a populationbased perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil.application/pdfengTrials (Online). London. Vol. 12 (2011), 7 p.Prevenção de doençasPré-hipertensãoHipertensãoPrevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trialEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000778193.pdf000778193.pdfTexto completo (inglês)application/pdf336084http://www.lume.ufrgs.br/bitstream/10183/30374/1/000778193.pdf525477ab78799896deb4bdfb83df9e54MD51TEXT000778193.pdf.txt000778193.pdf.txtExtracted Texttext/plain28138http://www.lume.ufrgs.br/bitstream/10183/30374/2/000778193.pdf.txt3e7867a5979454f7ed666b9613adf9c7MD52THUMBNAIL000778193.pdf.jpg000778193.pdf.jpgGenerated Thumbnailimage/jpeg1768http://www.lume.ufrgs.br/bitstream/10183/30374/3/000778193.pdf.jpg46c03d15a886a9bfd4470a395b94e06dMD5310183/303742023-06-29 03:29:42.381208oai:www.lume.ufrgs.br:10183/30374Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-06-29T06:29:42Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
title Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
spellingShingle Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
Fuchs, Flávio Danni
Prevenção de doenças
Pré-hipertensão
Hipertensão
title_short Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
title_full Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
title_fullStr Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
title_full_unstemmed Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
title_sort Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
author Fuchs, Flávio Danni
author_facet Fuchs, Flávio Danni
Fuchs, Sandra Cristina Pereira Costa
Moreira, Leila Beltrami
Gus, Miguel
Nobrega, Antonio Claudio Lucas da
Figueiredo, Carlos Eduardo Poli de
Mion Junior, Décio
Bortolotto, Luiz Aparecido
Consolim-Colombo, Fernanda Marciano
Nobre, Fernando
Coelho, Eduardo Barbosa
Martin, Jose Fernando Vilela
Moreno Junior, Heitor
Cesarino, Evandro José
Franco, Roberto Jorge da Silva
Brandão, Andréa Araujo
Sousa, Marcos Roberto de
Ribeiro, Antônio Luiz Pinho
Jardim, Paulo Cesar Brandao Veiga
Afiune Neto, Abrahão
Scala, Luiz César Nazário
Gomes, Marco Antônio Mota
Chaves, Hilton
Alves, João Guilherme Bezerra
Sobral Filho, Dário Celestino
Silva, Ricardo Pereira e
Figueiredo Neto, José Albuquerque de
Irigoyen, Maria Claudia Costa
Castro, Iran
Steffens, André Avelino
Schlatter, Rosane Paixão
Mello, Renato Gorga Bandeira de
Mosele, Francisca
Ghizzoni, Flávia
Silva, Otávio Berwanger da
author_role author
author2 Fuchs, Sandra Cristina Pereira Costa
Moreira, Leila Beltrami
Gus, Miguel
Nobrega, Antonio Claudio Lucas da
Figueiredo, Carlos Eduardo Poli de
Mion Junior, Décio
Bortolotto, Luiz Aparecido
Consolim-Colombo, Fernanda Marciano
Nobre, Fernando
Coelho, Eduardo Barbosa
Martin, Jose Fernando Vilela
Moreno Junior, Heitor
Cesarino, Evandro José
Franco, Roberto Jorge da Silva
Brandão, Andréa Araujo
Sousa, Marcos Roberto de
Ribeiro, Antônio Luiz Pinho
Jardim, Paulo Cesar Brandao Veiga
Afiune Neto, Abrahão
Scala, Luiz César Nazário
Gomes, Marco Antônio Mota
Chaves, Hilton
Alves, João Guilherme Bezerra
Sobral Filho, Dário Celestino
Silva, Ricardo Pereira e
Figueiredo Neto, José Albuquerque de
Irigoyen, Maria Claudia Costa
Castro, Iran
Steffens, André Avelino
Schlatter, Rosane Paixão
Mello, Renato Gorga Bandeira de
Mosele, Francisca
Ghizzoni, Flávia
Silva, Otávio Berwanger da
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Fuchs, Flávio Danni
Fuchs, Sandra Cristina Pereira Costa
Moreira, Leila Beltrami
Gus, Miguel
Nobrega, Antonio Claudio Lucas da
Figueiredo, Carlos Eduardo Poli de
Mion Junior, Décio
Bortolotto, Luiz Aparecido
Consolim-Colombo, Fernanda Marciano
Nobre, Fernando
Coelho, Eduardo Barbosa
Martin, Jose Fernando Vilela
Moreno Junior, Heitor
Cesarino, Evandro José
Franco, Roberto Jorge da Silva
Brandão, Andréa Araujo
Sousa, Marcos Roberto de
Ribeiro, Antônio Luiz Pinho
Jardim, Paulo Cesar Brandao Veiga
Afiune Neto, Abrahão
Scala, Luiz César Nazário
Gomes, Marco Antônio Mota
Chaves, Hilton
Alves, João Guilherme Bezerra
Sobral Filho, Dário Celestino
Silva, Ricardo Pereira e
Figueiredo Neto, José Albuquerque de
Irigoyen, Maria Claudia Costa
Castro, Iran
Steffens, André Avelino
Schlatter, Rosane Paixão
Mello, Renato Gorga Bandeira de
Mosele, Francisca
Ghizzoni, Flávia
Silva, Otávio Berwanger da
dc.subject.por.fl_str_mv Prevenção de doenças
Pré-hipertensão
Hipertensão
topic Prevenção de doenças
Pré-hipertensão
Hipertensão
description Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a populationbased intervention to prevent the incidence of hypertension and the development of target-organ damage. Methods: This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. Discussion: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a populationbased perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil.
publishDate 2011
dc.date.accessioned.fl_str_mv 2011-07-27T06:00:47Z
dc.date.issued.fl_str_mv 2011
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/30374
dc.identifier.issn.pt_BR.fl_str_mv 1745-6215
dc.identifier.nrb.pt_BR.fl_str_mv 000778193
identifier_str_mv 1745-6215
000778193
url http://hdl.handle.net/10183/30374
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Trials (Online). London. Vol. 12 (2011), 7 p.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/30374/1/000778193.pdf
http://www.lume.ufrgs.br/bitstream/10183/30374/2/000778193.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/30374/3/000778193.pdf.jpg
bitstream.checksum.fl_str_mv 525477ab78799896deb4bdfb83df9e54
3e7867a5979454f7ed666b9613adf9c7
46c03d15a886a9bfd4470a395b94e06d
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1815447426415198208